Details
| Stereochemistry | ACHIRAL |
| Molecular Formula | 3C9H7O4.Al |
| Molecular Weight | 564.43 |
| Optical Activity | NONE |
| Defined Stereocenters | 0 / 0 |
| E/Z Centers | 0 |
| Charge | 0 |
SHOW SMILES / InChI
SMILES
[Al+3].CC(=O)OC1=C(C=CC=C1)C([O-])=O.CC(=O)OC2=C(C=CC=C2)C([O-])=O.CC(=O)OC3=C(C=CC=C3)C([O-])=O
InChI
InChIKey=GKJRJGXKDYCFNF-UHFFFAOYSA-K
InChI=1S/3C9H8O4.Al/c3*1-6(10)13-8-5-3-2-4-7(8)9(11)12;/h3*2-5H,1H3,(H,11,12);/q;;;+3/p-3
Aspirin is a nonsteroidal anti-inflammatory drug. Aspirin is unique in this class of drugs because it irreversibly inhibits both COX-1 and COX-2 activity by acetylating a serine residue (Ser529 and Ser516, respectively) positioned in the arachidonic acid-binding channel, thus inhibiting the synthesis of prostaglandins and reducing the inflammatory response. The drug is used either alone or in combination with other compounds for the treatment of pain, headache, as well as for reducing the risk of stroke and heart attacks in patients with brain ischemia and cardiovascular diseases.
Approval Year
Targets
| Primary Target | Pharmacology | Condition | Potency |
|---|---|---|---|
Target ID: P23219|||Q5T7T7 Gene ID: 5742.0 Gene Symbol: PTGS1 Target Organism: Homo sapiens (Human) |
1.2 µM [IC50] | ||
Target ID: P35354 Gene ID: 5743.0 Gene Symbol: PTGS2 Target Organism: Homo sapiens (Human) |
5.2 µM [IC50] |
Conditions
| Condition | Modality | Targets | Highest Phase | Product |
|---|---|---|---|---|
| Primary | SYNALGOS-DC Approved UseSYNALGOS-DC is a combination of dihydrocodeine, an opioid agonist, aspirin, a nonsteroidal anti-inflammatory drug, and caffeine, a methylxanthine, and is indicated for the management of pain severe enough to require an opioid analgesic and for which alternative treatments are inadequate. Launch Date1958 |
|||
| Primary | FIORINAL Approved UseFIORINAL is indicated for the relief of the symptom complex of tension (or muscle contraction) headache. Evidence supporting the efficacy and safety of Fiorinal in the treatment of multiple recurrent headaches is unavailable. Caution in this regard is required because butalbital is habit-forming and potentially abusable. Launch Date1976 |
|||
| Preventing | DURLAZA Approved UseDURLAZA is a nonsteroidal anti-inflammatory drug indicated to reduce the risk of death and myocardial infarction (MI) in patients with chronic coronary artery disease, such as patients with a history of MI or unstable angina pectoris or with chronic stable angina and to reduce the risk of death and recurrent stroke in patients who have had an ischemic stroke or transient ischemic attack. Launch Date2015 |
|||
| Preventing | AGGRENOX Approved UseAGGRENOX is indicated to reduce the risk of stroke in patients who have had transient ischemia of the brain or completed ischemic stroke due to thrombosis. Launch Date1999 |
Cmax
| Value | Dose | Co-administered | Analyte | Population |
|---|---|---|---|---|
54.25 mg/L EXPERIMENT https://www.ncbi.nlm.nih.gov/pubmed/24672263 |
500 mg single, intravenous dose: 500 mg route of administration: Intravenous experiment type: SINGLE co-administered: |
ASPIRIN plasma | Homo sapiens population: HEALTHY age: ADULT sex: UNKNOWN food status: UNKNOWN |
|
4.84 mg/L EXPERIMENT https://www.ncbi.nlm.nih.gov/pubmed/24672263 |
500 mg single, oral dose: 500 mg route of administration: Oral experiment type: SINGLE co-administered: |
ASPIRIN plasma | Homo sapiens population: HEALTHY age: ADULT sex: UNKNOWN food status: UNKNOWN |
AUC
| Value | Dose | Co-administered | Analyte | Population |
|---|---|---|---|---|
10.31 mg × h/L EXPERIMENT https://www.ncbi.nlm.nih.gov/pubmed/24672263 |
500 mg single, intravenous dose: 500 mg route of administration: Intravenous experiment type: SINGLE co-administered: |
ASPIRIN plasma | Homo sapiens population: HEALTHY age: ADULT sex: UNKNOWN food status: UNKNOWN |
|
5.12 mg × h/L EXPERIMENT https://www.ncbi.nlm.nih.gov/pubmed/24672263 |
500 mg single, oral dose: 500 mg route of administration: Oral experiment type: SINGLE co-administered: |
ASPIRIN plasma | Homo sapiens population: HEALTHY age: ADULT sex: UNKNOWN food status: UNKNOWN |
T1/2
| Value | Dose | Co-administered | Analyte | Population |
|---|---|---|---|---|
0.322 h EXPERIMENT https://www.ncbi.nlm.nih.gov/pubmed/24672263 |
500 mg single, intravenous dose: 500 mg route of administration: Intravenous experiment type: SINGLE co-administered: |
ASPIRIN plasma | Homo sapiens population: HEALTHY age: ADULT sex: UNKNOWN food status: UNKNOWN |
|
0.422 h EXPERIMENT https://www.ncbi.nlm.nih.gov/pubmed/24672263 |
500 mg single, oral dose: 500 mg route of administration: Oral experiment type: SINGLE co-administered: |
ASPIRIN plasma | Homo sapiens population: HEALTHY age: ADULT sex: UNKNOWN food status: UNKNOWN |
Funbound
| Value | Dose | Co-administered | Analyte | Population |
|---|---|---|---|---|
68% |
ASPIRIN plasma | Homo sapiens population: UNKNOWN age: UNKNOWN sex: UNKNOWN food status: UNKNOWN |
Overview
| CYP3A4 | CYP2C9 | CYP2D6 | hERG |
|---|---|---|---|
OverviewOther
Drug as perpetrator
| Target | Modality | Activity | Metabolite | Clinical evidence |
|---|---|---|---|---|
| no | ||||
| no | ||||
| no | ||||
Page: - |
yes | |||
| yes | ||||
| yes | ||||
| yes | ||||
Page: - |
yes |
Drug as victim
| Target | Modality | Activity | Metabolite | Clinical evidence |
|---|---|---|---|---|
| no | ||||
| no | ||||
| no | ||||
| no | ||||
| no | ||||
| no | ||||
| no | ||||
| no | ||||
| no | ||||
| no | ||||
| no | ||||
| no | ||||
| no | ||||
| yes [Km 1242 uM] | ||||
| yes [Km 2337 uM] | ||||
| yes [Km 278.6 uM] | ||||
| yes [Km 40.7 uM] | ||||
| yes [Km 683.1 uM] | ||||
| yes [Km 698.2 uM] | ||||
| yes [Km 94.2 uM] | ||||
| yes | ||||
| yes | ||||
| yes | ||||
| yes | ||||
| yes | ||||
| yes | ||||
| yes | ||||
| yes |
PubMed
| Title | Date | PubMed |
|---|---|---|
| Pharmacotherapies for cocaine dependence. | 2000 Dec |
|
| The discovery of aspirin: a reappraisal. | 2000 Dec 23-30 |
|
| Novel platelet inhibitors. | 2001 |
|
| Human herpesvirus 8 K1-associated nuclear factor-kappa B-dependent promoter activity: role in Kaposi's sarcoma inflammation? | 2001 |
|
| Cardiac risk factors, medication, and recurrent clinical events after acute coronary disease; a prospective cohort study. | 2001 Feb |
|
| Non-steroidal anti-inflammatory drugs and gastrointestinal damage-problems and solutions. | 2001 Feb |
|
| A novel synthetic inhibitor of factor Xa decreases early reocclusion and improves 24-h patency after coronary fibrinolysis in dogs. | 2001 Feb |
|
| The effects of diaspirin cross-linked hemoglobin on the tone of human saphenous vein. | 2001 Feb |
|
| Renal function and intensive lowering of blood pressure in hypertensive participants of the hypertension optimal treatment (HOT) study. | 2001 Feb |
|
| Risk factors for severe hemorrhagic transformation in ischemic stroke patients treated with recombinant tissue plasminogen activator: a secondary analysis of the European-Australasian Acute Stroke Study (ECASS II). | 2001 Feb |
|
| Use of aspirin, epistaxis, and untreated hypertension as risk factors for primary intracerebral hemorrhage in middle-aged and elderly people. | 2001 Feb |
|
| Antiplatelet drugs for prevention of pre-eclampsia and its consequences: systematic review. | 2001 Feb 10 |
|
| Systematic review of long term anticoagulation or antiplatelet treatment in patients with non-rheumatic atrial fibrillation. | 2001 Feb 10 |
|
| Heterogenous nature of flow-mediated dilatation in human conduit arteries in vivo: relevance to endothelial dysfunction in hypercholesterolemia. | 2001 Feb 2 |
|
| Addition of hydrophilic and lipophilic compounds of biological relevance to the monoolein/water system. I. Phase behavior. | 2001 Jan |
|
| Present treatment options for unstable angina and non-Q-wave myocardial infarction. | 2001 Jan |
|
| Antithrombotic agents in coronary artery disease. | 2001 Jan |
|
| Antithrombotic therapy in patients with mechanical and biological prosthetic heart valves. | 2001 Jan |
|
| Antithrombotic therapy in atrial fibrillation. | 2001 Jan |
|
| Use of antithrombotic agents during pregnancy. | 2001 Jan |
|
| Platelet-active drugs : the relationships among dose, effectiveness, and side effects. | 2001 Jan |
|
| Gastric mucosal resistance to acute injury in experimental portal hypertension. | 2001 Jan |
|
| Angioplasty increases coronary sinus F2-isoprostane formation: evidence for in vivo oxidative stress during PTCA. | 2001 Jan |
|
| Multiple endothelial injury in epicardial coronary artery induces downstream microvascular spasm as well as remodeling partly via thromboxane A2. | 2001 Jan |
|
| Lp(a) lipoprotein--an independent risk factor for coronary heart disease after menopause. | 2001 Jan |
|
| Prehospital management of rapid atrial fibrillation: recommendations for treatment protocols. | 2001 Jan |
|
| Endogenous nitric oxide and prostaglandins synergistically counteract thromboembolism in arterioles but not in venules. | 2001 Jan |
|
| Disaggregation of in vitro preformed platelet-rich clots by abciximab increases fibrin exposure and promotes fibrinolysis. | 2001 Jan |
|
| Selectivity of recombinant human leukotriene D(4), leukotriene B(4), and lipoxin A(4) receptors with aspirin-triggered 15-epi-LXA(4) and regulation of vascular and inflammatory responses. | 2001 Jan |
|
| [Leukocytoclastic vasculitis associated with ticlopidine]. | 2001 Jan |
|
| Antithrombotic therapy in cardiac stent patients. | 2001 Jan |
|
| Anticoagulation and heart failure. | 2001 Jan |
|
| Is optimal antithrombotic therapy after myocardial infarction well defined? | 2001 Jan |
|
| Reduced risk of colorectal cancer among long-term users of aspirin and nonaspirin nonsteroidal antiinflammatory drugs. | 2001 Jan |
|
| Diabetes mellitus with left transverse sinus thrombosis and right transverse sinus aplasia. | 2001 Jan |
|
| Active-control trials: how would a new agent compare with placebo? A method illustrated with clopidogrel, aspirin, and placebo. | 2001 Jan |
|
| Review article: the gastrointestinal safety profile of rofecoxib, a highly selective inhibitor of cyclooxygenase-2, in humans. | 2001 Jan |
|
| Prevention of pre-eclampsia: status and perspectives 2000. | 2001 Jan |
|
| Hemoglobin and methemoglobin concentrations after large-dose infusions of diaspirin cross-linked hemoglobin. | 2001 Jan |
|
| Effect of acetylsalicylic acid on endogenous I kappa B kinase activity in lung epithelial cells. | 2001 Jan |
|
| Another reason for taking aspirin. | 2001 Jan |
|
| Hypothesized treatment for migraines using low doses of tryptophan, niacin, calcium, caffeine, and acetylsalicylic acid. | 2001 Jan |
|
| Low-grade exercise enhances platelet aggregability in patients with obstructive coronary disease independently of myocardial ischemia. | 2001 Jan 1 |
|
| Salicylate and cocaine: interactive toxicity during chicken mid-embryogenesis. | 2001 Jan 15 |
|
| Blood donations and risk of coronary heart disease in men. | 2001 Jan 2 |
|
| Local delivery of enoxaparin to decrease restenosis after stenting: results of initial multicenter trial: Polish-American Local Lovenox NIR Assessment study (The POLONIA study). | 2001 Jan 2 |
|
| Authors' reply on aspirin for primary prevention. | 2001 Jan 20 |
|
| Superiority of clopidogrel versus aspirin in patients with prior cardiac surgery. | 2001 Jan 23 |
|
| Pharmacological properties of a newly synthesized H(+)/K(+) ATPase inhibitor, 1-(2-methyl-4-methoxyphenyl)-4-. | 2001 Jan 5 |
|
| Drug Points: tachycardia associated with moxifloxacin. | 2001 Jan 6 |
Sample Use Guides
Severe pain: Initiate treatment with two capsules (1 capsule contains 16 mg dihydrocodeine bitartrate, 356.4 mg aspirin, and 30 mg caffeine) orally every 4 hours as needed for pain. Headache: One or 2 capsules (1 capsule contains 50 mg butalbital, 325 mg aspirin and 40 mg caffeine) every 4 hours. Total daily dose should not exceed 6 capsules. Prevention of stoke and heart attacks: the recommended dose is one capsule of aspirin (162.5 mg) once daily. Take the capsules with a full glass of water at the same time each day. Prevention of stroke (in combination with dipyridamole): the recommended dose is one capsule (200 mg dipyridamole and 25 mg aspirin) given orally twice daily.
Route of Administration:
Enteral
Human platelet-rich plasma was incubated with various aspirin concentrations (10, 20, 50, 100, 200, 300, 400, 500 uM) at 37C for up to 4.5 h. Platelet aggregation and thromboxane generation were measured. Inhibition of platelet aggregation and thromboxane formation by 10 uM aspirin was maximal by 90 min. There was progressive inhibition by 3 uM aspirin during incubation for 270 min. By the end of this time there was also significant inhibition by 1 uM aspirin.
| Name | Type | Language | ||
|---|---|---|---|---|
|
Common Name | English | ||
|
Systematic Name | English | ||
|
Systematic Name | English |
| Code System | Code | Type | Description | ||
|---|---|---|---|---|---|
|
10030780
Created by
admin on Sat Dec 16 09:11:25 GMT 2023 , Edited by admin on Sat Dec 16 09:11:25 GMT 2023
|
PRIMARY | |||
|
ED7L5F608H
Created by
admin on Sat Dec 16 09:11:25 GMT 2023 , Edited by admin on Sat Dec 16 09:11:25 GMT 2023
|
PRIMARY | |||
|
29825-08-9
Created by
admin on Sat Dec 16 09:11:25 GMT 2023 , Edited by admin on Sat Dec 16 09:11:25 GMT 2023
|
PRIMARY |
PARENT (SALT/SOLVATE)
SUBSTANCE RECORD
